CatalystFDA/Bio

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Phase 2 initiation milestone for VAV1 degrader MRT-6160 signals clinical progress.

What changed

Phase 2 initiation milestone for VAV1 degrader MRT-6160 signals clinical progress.

Why it matters

Phase 2 initiation milestone for VAV1 degrader MRT-6160 signals clinical progress. — impact context not separately stored; see What changed.

Sources